Technology | September 14, 2012

Mayo Clinic is first facility approved to manufacture Choline C-11 injection


September 14, 2012 — The U.S. Food and Drug Administration (FDA) has approved the production and use of Choline C-11 injection, a positron emission tomography (PET) imaging agent used to help detect recurrent prostate cancer. Choline C-11 injection is administered intravenously to produce an image that helps to locate specific body sites for follow-up tissue sampling and testing in men with recurrent prostate cancer.

PET imaging with Choline C-11 injection is performed in patients whose blood prostate specific antigen (PSA) levels are increasing after earlier treatment for prostate cancer. An elevated PSA result suggests that prostate cancer may have returned, even though conventional imaging tests, such as computed tomography (CT), have not shown any signs of cancer. PET imaging is not a replacement for tissue sampling and testing.

Choline C-11 injection must be produced in a specialized facility and administered to patients shortly after its production. While PET imaging with Choline C-11 injection has been performed at a few facilities over the past several years, none of these facilities were approved by the FDA to manufacture the agent. The Food and Drug Administration Modernization Act directed the agency to establish appropriate approval procedures and current good manufacturing practice requirements for all PET products marketed and used in the United States. The Mayo Clinic is now the first FDA-approved facility to produce Choline C-11 injection.

“Choline C-11 injection provides an important imaging method to help detect the location of prostate cancer in patients whose blood tests suggest recurrent cancer when other imaging tests are negative,” said Charles Ganley, M.D., director of the Office of Drug Evaluation IV in FDA’s Center for Drug Evaluation and Research. “The FDA’s approval of Choline C-11 injection at the Mayo Clinic provides assurance to patients and healthcare professionals they are using a product that is safe, effective and produced according to current good manufacturing practices.”

The safety and effectiveness of Choline C-11 injection were verified by a systematic review of published study reports. Four independent studies examined a total of 98 patients with elevated blood PSA levels but no sign of recurrent prostate cancer on conventional imaging. After PET imaging with Choline C-11, the patients underwent tissue sampling of the abnormalities detected on the PET scans.

In each of the four studies, at least half the patients who had abnormalities detected on PET scans also had recurrent prostate cancer confirmed by tissue sampling of the abnormal areas. PET scan errors also were reported. Depending on the study, falsely positive PET scans were observed in 15 percent to 47 percent of the patients. These findings underscore the need for confirmatory tissue sampling of abnormalities detected with Choline C-11 injection PET scans. Aside from an uncommon, mild skin reaction at the injection site, no side effects to Choline C-11 injection were reported.

Choline C-11 injection is manufactured and distributed by the Mayo Clinic PET Radiochemistry Facility in Rochester, Minn.

For more information: www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm085783.htm


Related Content

News | ASTRO

June 21, 2024 — The American Society for Radiation Oncology (ASTRO) announced today that following a nationwide search ...

Time June 21, 2024
arrow
News | Nuclear Imaging

June 20, 2024 — GE HealthCare joined the world’s top medical and academic institutions at the Society of Nuclear ...

Time June 20, 2024
arrow
News | Proton Therapy

June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...

Time June 14, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
News | SNMMI

June 13, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted more than 8,000 physicians ...

Time June 13, 2024
arrow
News | PET-CT

June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 13, 2024
arrow
News | Radiology Business

June 12, 2024 — Cathy Sue Cutler, PhD, FSNMMI, chair of the Isotope Research and Production Department at Brookhaven ...

Time June 12, 2024
arrow
News | SPECT-CT

June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac ...

Time June 11, 2024
arrow
News | PET Imaging

June 11, 2024 — A new ultra-high-performance brain PET system allows for the direct measurement of brain nuclei as never ...

Time June 11, 2024
arrow
News | Radiology Business

June 10, 2024 — Jean-Luc C. Urbain, MD, PhD, FASNC, professor of Radiology/Nuclear Medicine and Medicine, has been named ...

Time June 10, 2024
arrow
Subscribe Now